The proto-oncogene c-rel is a member of the rel/NF-B transcription factor family (for recent reviews, see Refs. [1] [2] [3] [4] [5] [6] . NF-B is highly regulated and is activated by a large variety of stimuli, such as cytokines, growth factors, oxidants, UV irradiation, infections, and physical or oxidative stress. NF-B plays a pivotal role in the regulation of many genes involving immune and inflammatory responses, healing and regeneration processes, and embryogenesis. This family of proteins share sequence homology in the N-terminal Rel homology region, which is responsible for DNA binding, dimerization, and inhibitor association. c-Rel is expressed at high levels in hematopoietic cells and regulates the expression of different genes in B and T cells that are crucial for cell division, apoptosis, and immune functions. Although c-rel knockout mice develop normally, they exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression (7) . In most cells, Rel/NF-B proteins serve an antiapoptosis function, and overexpression of c-Rel results in cellular transformation (reviewed in Ref. 8) . However, in developing chicken embryos and in chicken bone marrow cells, high levels of c-Rel expression are associated with programmed cell death (9) . Despite these seemingly contradictory reports, regulation of c-Rel expression undoubtedly plays an important role in maintaining normal growth and development. Alterations or amplification of the rel locus have been found in human lymphomas (reviewed in Ref. 10) , and viral transduction of c-rel resulted in v-rel, the transforming gene of the reticuloendotheliosis virus, strain T (REV-T) (4, 11) . REV-T is a highly virulent retrovirus that induces a fatal lymphoid leukemia in galliform birds within 7-10 days after infection. The v-Rel protein differs structurally from c-Rel in that v-Rel lacks the N-terminal two amino acids and the C-terminal 118 amino acids that are normally present in c-Rel. Instead, v-Rel has viral env sequences at both termini and contains multiple amino acid substitutions and small inframe deletions in the middle (11, 12) . Recently, transgenic mice overexpressing v-Rel were shown to develop aggressive T-cell lymphoma/leukemia, further demonstrating the oncogenic potential of v-Rel in mammals (13) .
The extralysosomal, energy-dependent ubiquitin-proteasome (Ub-Pr) 1 pathway is a major mechanism used to regulate the turnover of many cellular proteins, which include highly abnormal proteins, short lived and long lived proteins (for recent reviews, see 14 -19) . The pathway, present in both the cytoplasm and nucleus, consists of two distinct and sequential steps. The target protein is first conjugated with multiple ubiquitin molecules and then translocated to and degraded by the large 26 S proteasome (reviewed in Ref. 20) . The list of Ub-Pr pathway substrates has been growing rapidly. Prominent examples include proto-oncogene products, transcription factors, cell cycle regulators, cytokine and growth factor receptors, major histocompatibility complex class I molecules, the cystic fibrosis transmembrane conductance regulator, and others.
Activation of NF-B also involves the Ub-Pr degradation pathway. In the absence of inducers, the NF-B dimeric transcription factor is sequestered in the cytoplasm through physical association with a member of the IB family of inhibitor proteins. In response to extracellular stimuli, IB␣ (the best studied inhibitor) is phosphorylated, ubiquitinated, and degraded by the proteasome, thus releasing the NF-B dimer for translocation into the nucleus. NF-B inhibitors, including p105 (21, 22) , p100, IB␣ (23) (24) (25) , IB␤ (26) , and IB⑀ (27) , were shown to be subject to Ub-Pr-mediated degradation. In this study, we demonstrate that the degradation of the NF-B family protein, c-Rel, also involves the Ub-Pr pathway, and C-terminal sequence of c-Rel plays an important role in the degradation of c-Rel.
MATERIALS AND METHODS
Cell Lines and Chemicals-MT-2, HUT102, and 81-66 are HTLV-Iinfected human T-cell lines (28) . Jurkat is a T-cell line established from a patient with T-cell leukemia (America Type Culture Collection). DB and CA46 are B-lymphoma cell lines (24) . All human T and B cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum, and antibiotics (50 units/ml penicillin and 50 g/ml streptomycin). DT95, an avian IgM-producing mature B cell line (29) , was cultured in Dulbecco's modified Eagle's medium supplemented with 5% bovine calf serum, 5% chicken serum, and antibiotics. NIH3T3 and monkey COS cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum and antibiotics. Proteasome inhibitors, lactacystin (LC) and LLnL (Calpain inhibitor I; N-acetyl-L-leucinyl-L-leucinyl-norleucinal) were purchased from Corey Laboratory (Harvard University) and Sigma, respectively. N-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), N-␣-p-tosyl-L-lysine chloromethyl ketone (TLCK), and iodoacetamide (an isopeptidase inhibitor) were purchased from Sigma.
Western Blot and Immunoprecipitation Analyses-For Fig. 1a , the cytoplasmic and nuclear fractions were extracted as described previously (30) . For Fig. 2b , Jurkat cells were lysed with Nonidet P-40 buffer (20 mM Tris/HCl, pH 7.6, 150 mM NaCl, 1% Nonidet P-40, 2 mM EDTA) containing protease inhibitors (1% aprotinin, 50 M LLnL, 70 g/ml phenylmethanesulfonyl fluoride, 40 g/ml TPCK, 5 g/ml TLCK, 5 g/ml leupeptin) and 10 mM iodoacetamide. The Nonidet P-40-soluble and -insoluble fractions were further analyzed by immunoprecipitations and Western blot. For Western analysis, equal amounts of protein (assayed with the BCA kit; Pierce) or fractions isolated from equal number cells were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylpyrrolidone membranes. The membrane was blocked, washed, incubated with antiserum (typically at 1:1000) followed by reacting with peroxidase-conjugated antirabbit immunoglobulin serum (Boehringer Mannheim), and developed by the enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). For immunoprecipitation analysis, cells were lysed in radioimmune precipitation buffer (20 mM Tris/HCl, pH 7.6, 150 mM NaCl, 2 mM EDTA, 1% deoxycholate, 1% Triton X-100) or in other specified buffers containing protease inhibitors and 10 mM iodoacetamide. The lysates were clarified by centrifugation at 12,000 ϫ g for 30 min and then incubated with individual antiserum in the presence or absence of the competing peptide (2 g for each l of antiserum). The immune complexes were collected with Protein A-Sepharose beads, washed with radioimmune precipitation buffer, boiled, resolved by SDS-PAGE, transferred onto membranes, and further analyzed.
Expression Plasmids-The human c-Rel expression plasmid pRC/ CMV-h-rel, kindly provided by N. Rice (NCI-Frederick Cancer Research and Development Center), was used in both in vivo and in vitro expressions. All of the expression plasmids containing C-terminally truncated avian c-rel were constructed using pc-rel2 (31) as the template. Synthetic oligonucleotide adapters (Table I, column 5) containing stop codons (underlined) were inserted between specific restriction sites in c-rel coding sequence (columns 3 and 4) and the BssHII site of pc-rel2, thus replacing a portion of c-rel coding sequence. For pc-rel⌬118, stop codon was introduced by oligonucleotide site-directed mutagenesis, in which the mutagenic oligonucleotide (5Ј-CGTGAACATGTAGACCAAT-GAC-3Ј) and the MutaGene in vitro mutagenesis kit (Bio-Rad) were used. Sequences around the insertion sites and sequences subjected to site-directed mutagenesis were verified by sequencing. Plasmids designated pc-rel⌬X (X indicates the number of deleted amino acids) were used in the in vitro transcription and translation for further analyses.
Antisera-The previously published anti-(c-Rel 1135) and anti-(c-Rel 265) sera were generated against peptides corresponding to residues 493-509 and 573-587 of human c-Rel, respectively (32) . Other human c-Rel antisera, purchased from Santa Cruz Biotechnology, Inc. (catalog no. sc-70) and Upstate Biotechnology, Inc. (catalog no. 06 -421), were raised against peptides corresponding to murine c-Rel residues 152-176 and human c-Rel residues 573-587, respectively. Anti-ubiquitin immune sera were purchased from Sigma and Dako, Inc. Avian c-Rel antisera V1, V2, and V3 (33) were generated against residues 115-292, 293-458, and 425-437 of avian c-Rel, respectively.
In Vitro Assays-Human c-Rel, avian c-Rel, and C-terminally truncated c-Rel⌬X proteins were synthesized with [ 35 S]methionine in a reticulocyte lysate-based in vitro transcription/translation system (Promega). The 35 S-labeled proteins were purified away from the free [ 35 S]methionine by concentrating in Centricon 30 (Amicon) and used as the substrates in the in vitro degradation and conjugation assays (24, 34) , in which S100 extracted from human B cell line CA46 or avian DT95 was used as the enzyme source. For degradation assays, master reaction mixture containing substrate (1 l/time point), dialyzed Ub (6 g/time point), 12 mM Tris-HCl, pH 7.5, 60 mM KCl, 3.5 mM MgCl 2 , 5 mM CaCl 2 , 1 mM dithiothreitol, and 1 mM ATP was prepared and aliquoted into separate tubes on ice. At each time point, 50 g of S100 was added to individual tubes to start the reaction at 37°C, and the final volume of each reaction was adjusted to 50 l. All of the reactions were simultaneously terminated by boiling in SDS-sample buffer, analyzed by SDS-PAGE followed by Western transfer and autoradiography. For conjugation assays, reactions were carried out as in degradation assays except that okadaic acid (1 g/ml), proteasome inhibitor LLnL (100 M), and isopeptidase inhibitor iodoacetamide (10 mM) were included (34) .
Transfection-Transient transfection was carried out using the SuperFect Transfection kit (Qiagen) according to the instructions. The coding sequence of chicken c-rel (35) was cloned as a XhoI-BssHII fragment from pc-rel2 between XhoI and MluI sites of mammalian expression vector pCI-neo (Promega). An aliquot of 5 g of DNA was used to transfect 4 ϫ 10 5 NIH3T3 or COS cells seeded in each 60-mm dish. After transfection for 2.5 h, cells were washed and grown in fresh medium for 40 h. Cells were then either treated with inhibitors or used for the pulse-chase experiments.
RESULTS

High Molecular Weight c-Rel Proteins Are Present in HTLV-I-infected Cells and in B-lymphoma Cells-
We and others previously showed that NF-B is constitutively activated and c-Rel is highly induced in both HTLV-I-infected T cells and B-lymphoma cells (28, 36, 37) . Immunoblotting analyses showed that, in addition to the 80-kDa full-length c-Rel, high M r proteins were detected in both the cytoplasmic and the nuclear lysates 
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of HTLV-I-infected cells (Fig. 1a) . These high M r proteins were reactive to a number of c-Rel antisera (one such experiment is shown in Fig. 1a, lanes 1-6) but not to the corresponding preimmune sera (data not shown) or the immune sera preincubated with the competing peptides (lanes 7 and 8). To further characterize these c-Rel proteins, cell lysates from a B cell lymphoma cell line were immunoprecipitated with c-Rel-specific antiserum in the absence (Fig. 1b, lane 1) or presence (lane 2) of the competing peptide, and the immune complexes were separated and analyzed by immunoblotting with c-Rel antiserum. Reactivities in a ladder-like pattern, indicative of multiubiquitin conjugates, were detected only in the former (lane 1), suggesting that c-Rel may be subject to ubiquitin modification.
High Molecular Weight c-Rel Are Ubiquitinated c-Rel Conjugates-To confirm that the high M r anti-c-Rel-reactive proteins were indeed the ubiquitinated c-Rel, serum-starved Jurkat cells were stimulated with serum, which induced the expression of c-Rel, in the presence of a proteasome-specific inhibitor, LC (Fig. 2a) (17) . The cell lysates were immunoprecipitated with c-Rel-specific antiserum, and the immune complexes were analyzed by SDS-PAGE followed by immunoblotting with either c-Rel antiserum (lanes 1-3) or Ub antiserum (lanes 4 -6). As in Fig. 1b , high M r c-Rel-specific reactivity in a ladder-like pattern was detected after inhibitor treatment for 2 h (lane 3).
The similar high M r reactivity detected in anti-Ub immunoblotting (lane 6) further demonstrated that these high M r proteins are the bona fide ubiquitin-c-Rel conjugates. Similar results were also obtained using other proteasome inhibitors including MG132 and LLnL (also known as ALLN or Calpain inhibitor I) (data not shown).
We also treated Jurkat cells with the inhibitor LLnL, and measured the steady state level of c-Rel in Jurkat cells (Fig.  2b) . Interestingly, while the high M r c-Rel proteins expectedly accumulated during the inhibitor treatment, these high M r c-Rel proteins were detected mainly in the detergent-insoluble fractions (lanes 6 -10) . This result suggests that c-Rel is constantly ubiquitinated and that the ubiquitinated c-Rel tends to accumulate in the noncytoplasmic fractions.
Inhibition of Proteasome Activity Blocks Degradation of c-Rel and Promotes Accumulation of Ub-c-Rel
Conjugates-To demonstrate that the normal turnover of c-Rel is regulated by the Ub-Pr pathway, we treated cells with LLnL to block the proteasome activity and measured the stability of c-Rel. In cells expressing high levels of NF-B, e.g. B cells and certain T cells, c-Rel is often associated with other NF-B or IB family proteins, which may provide c-Rel physical protections against proteosomal degradation. To avoid this physical protection, we transiently overexpressed avian c-Rel in NIH3T3 cells, which have a low NF-B endogenous expression, treated the cells with LLnL, and analyzed the total cell lysates. Similar to Fig.  2 , immunoblot using c-Rel-specific antiserum revealed that the 80-kDa c-Rel was stabilized and that the high M r Ub-c-Rel conjugates accumulated in a time-dependent fashion (Fig. 3a) . Furthermore, we overexpressed avian c-Rel in monkey COS cells and performed pulse-chase experiments in the presence or absence of the proteasome inhibitor, LLnL (Fig. 3b) . Cells collected from each time point were lysed by boiling in SDS- 
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containing buffer, and the lysates were immunoprecipitated with c-Rel antiserum. Although c-Rel is relatively stable with an estimated half-life of slightly longer than 9 h in untreated cells (lanes 2-7) , the half-life of c-Rel in LLnL-treated cells is considerably longer than 9 h (lanes 8 -13) . It was noted that a decrease of c-Rel was detected at 20 h (lane 12) in treated cells, similar to that in the untreated cells (lane 6). However, this decrease was largely due to the cell death resulting from the long period of inhibitor treatment. More than 50% of the cells were dead after 20 h of LLnL treatment (data not shown). Importantly, the level of c-Rel in inhibitor-treated cells is significantly higher than that in the untreated cells at every time point (compare lanes 8 -13 with lanes 2-7, respectively), indicating that LLnL is capable of stabilizing c-Rel and inhibiting the normal degradation of c-Rel.
c-Rel Is Degraded by the Ub-Pr Pathway in in Vitro
Assays-To further study the Ub-Pr regulation of c-Rel, a cellfree, in vitro Ub-Pr degradation assay was used (22, 24) . In this assay, human c-Rel was in vitro transcribed and translated in the presence of [ 35 S]methionine and used as the substrate. The degradation can be demonstrated using c-Rel synthesized in either a reticulocyte lysate (Fig. 4, lanes 1-6) or a wheat germ (data not shown) translation system, or using endogenous c-Rel immunoprecipitated from cell lysates (data not shown). This in vitro degradation of c-Rel is Ub-Pr pathway-specific because c-Rel was not degraded in assays performed in the presence of proteasome inhibitors, lactacystin (lanes 7-9), LLnL (lanes 10 -12), MG132 (data not shown), or apyrase (an ATP remover) (data not shown). By contrast, TPCK (lanes [13] [14] [15] , TLCK (lanes 16 -18) , and weak bases (data not shown), inhibitors of chymotrypsin-like proteases, trypsin-like proteases, and lysosomes, respectively, did not inhibit the degradation. These results strongly suggest that the degradation of c-Rel is mediated by the proteasome pathway in the in vitro system.
C-terminal Sequence of c-Rel Plays an Important Role in Degradation-
In addition to the full-length 80-kDa c-Rel, a smaller protein with an apparent molecular mass of 45 kDa (p45) was also readily degraded in the in vitro assay (Fig. 4,  lanes 1-6; Fig. 5, lanes 1-4) . Presumably, p45 is either a c-Rel proteolytic fragment generated from the translation product in the rabbit reticulocyte system, or a smaller c-Rel translation product resulted from an internal initiation. To characterize p45, we immunoprecipitated the in vitro reactions (Fig. 5, lanes  1-4) with antisera specific to either the N-terminal (lanes 5-8) or the C-terminal (lanes 9 -12) sequence of c-Rel. The C-terminal specific antiserum precipitated both the full-length and p45 c-Rel, whereas the N-terminal specific antiserum only precipitated the full-length c-Rel, indicating that p45 lacks the Nterminal sequence. This result suggests that the N-terminal domain of c-Rel is not required in the in vitro degradation of c-Rel, and the C-terminal domain may play a more important role in mediating c-Rel degradation. Similar experiments were also performed in avian c-Rel, and the same conclusion was obtained (data not shown).
To examine the importance of the C-terminal sequences, a series of C-terminally truncated avian c-rel expression plasmids were constructed (Table I and Fig. 6a) , and used to translate the corresponding c-Rel proteins in vitro (Fig. 6b ). When these 35 S-labeled c-Rel variants were tested in the in vitro degradation assays (Fig. 7a) , interestingly, mutants with truncations larger than 118 amino acids displayed nearly complete resistance to degradation. PhosphorImager scanning (Molecular Dynamics, Inc. Sunnyvale, CA) revealed that about 80, 82, 100, and 100% of the input substrates remained at the end of the assay for mutants lacking the C-terminal 171, 231, 275, and 313 amino acids, respectively. In contrast, only 5, 10, and 25% of the input c-Rel remained for mutants missing the Cterminal 16, 55, and 118 amino acids, respectively (Fig. 7b) . Since c-Rel and v-Rel share sequence similarities only at the N-terminal 118 amino acids, these results seem to suggest that the region between residues 118 and 171 of c-Rel, i.e. the c-Rel-specific sequence immediately following the c-Rel/v-Rel homology domain, plays an important role in mediating c-Rel degradation. To determine whether the resistance to degradation resulted from a differential capability of ubiquitination, in vitro ubiquitin conjugation assays were performed (Fig. 7c) . Although ubiquitinated c-Rel could be detected in all mutants, wild type, ⌬16, ⌬55, and ⌬118 c-Rel variants appeared to have significantly higher conjugation efficiency than ⌬171, ⌬231, ⌬275, and ⌬313. These results are consistent with the degradation data and are compatible with the notion that the sequences between residues 118 and 171 of c-Rel may be the major ubiquitination sites or/and important for recognition by the ubiquitination machinery.
DISCUSSION
Certain inducers, e.g. bacterial LPS, activate NF-B with biphasic kinetics, an early transient phase and a late persistent phase (1-6). In the early phase, rapid degradation of IB␣ and concomitant nuclear translocation of the activated NF-B are   FIG. 4 . Proteasome-specific degradation of c-Rel in in vitro assays. 35 SLabeled in vitro translated human c-Rel protein was subjected to the cell-free in vitro degradation assay without inhibitors (lanes 1-6) or with one of the following inhibitors, 10 M LC, 50 M LLnL, 100 M TPCK, and 100 M TLCK. All reactions were terminated at the indicated times (in min) by boiling in SDS gel loading buffer and analyzed by SDS-PAGE, Western transfer, and autoradiography. The mobility of the full-length c-Rel is indicated.
FIG. 5. In vitro degradation of N-terminally truncated 45-kDa c-Rel.
The labeled human c-Rel was subjected to the in vitro degradation assay as described in Fig. 4 . The reaction at each time point was separated into three parts; one part was used for gel analysis ( lanes  1-4) , and the other two parts were boiled in radioimmune precipitation buffer containing 0.5% SDS and then diluted and immunoprecipitated with the N-terminal-specific anti-c-Rel serum (sc-70) (lanes 5-8) , or the C-terminal-specific anti-(c-Rel 265) serum (lanes 9 -12) .
c-Rel Degradation by Ub-Pr Pathway
detected within minutes after stimulation. It is transient, because the induced NF-B activity up-regulates the synthesis of IB␣, which subsequently inhibits the NF-B activity itself.
The late phase activation constitutes a prolonged induction of NF-B over hours and even days after stimulation. This prolonged activation results mainly from the degradation of IB␤ and an elevated level of the transcription factor. Activation of both early and late phases has been shown to be regulated, at least in part, by the Ub-Pr pathway. Specifically, when cells are stimulated, the IB molecules undergo site-specific phosphorylation and ubiquitination and then are degraded by the 26 S proteasome. The released dimeric NF-B enters the nucleus and induces expression of the target genes. In the present study, we report that in addition to IB molecules, the transcription factor c-Rel is also regulated by the Ub-Pr pathway. It is not likely that the c-Rel contained in the latent NF-B-IB␣ trimeric complex is degraded along with IB␣ in the early phase induction. Otherwise, a significant diminution of c-Rel would be detected, and a concomitant nuclear translocation of c-Rel would not take place. Our results show that when Jurkat cells were treated with the proteasome inhibitors, Ub-c-Rel conjugates accumulated in a time-dependent manner. This was detected in the presence (Fig. 2a) and the absence (Fig. 2b) of the extracellular inducers. We conclude that the basal turnover of c-Rel is mediated by the Ub-Pr pathway, and this level of regulation most likely is involved in the late phase of NF-B activation.
We recently identified a cellular ATPase, the 97-kDa valosincontaining protein (VCP), that co-purifies with IB␣ immune complexes and the 26 S proteasome (34) . IB␣-VCP binding requires the phosphorylation and ubiquitination of IB␣ and in turn is required for the degradation of IB␣. Because VCP was readily detected in IB␣ immune complexes, but not in c-Rel or RelA immunoprecipitates, we hypothesize that the binding of VCP to the ubiquitinated IB␣ disrupts the NF-B-IB␣ trimeric complex, thus liberating the NF-B dimer. The VCP-bound IB␣ is then transferred to the proteasome for degradation (34) . Our failure to detect VCP in c-Rel immune complexes suggests that binding to VCP is not a prerequisite for Ub-Prmediated degradation of c-Rel. However, we could not completely rule out the possibility that this is because Ub-c-Rel conjugates tend to be detergent-insoluble (Fig. 2b) , resulting in a low abundance of Ub-c-Rel in the lysates. In addition, this could result from low sensitivity of the available antisera to recognize the ubiquitin-modified c-Rel. The observations that Ub-IB␣ molecules are found mostly in the cytoplasm, whereas Ub-c-Rel conjugates are mainly detected in Nonidet P-40-insoluble noncytoplasmic fractions, may suggest a different location for c-Rel degradation. It appears that although both IB␣ and c-Rel are regulated by Ub-Pr pathways, there may exist signif- 
icant differences between the molecular mechanisms involved. A feature shared by many Ub-Pr substrates is that the proteins normally function within multimeric complexes or by interacting with other macromolecules within the cells. Through the physical association with other cellular proteins, the substrate is protected from the proteasome. Recent work suggests that the association of retinoblastoma protein or adenovirus transforming protein protects E2F-1 from degradation by the Ub-Pr pathway (38, 39) . This raises the possibility that the regions of the protein targeted for ubiquitination or degradation are those involved in protein-protein interactions. After the dissociation of the multimeric complexes, this region is exposed and targeted for degradation. Indeed, c-Rel is almost always physically associated with other NF-B components, through which c-Rel is stabilized and exhibits a relatively long half-life (15 h in DB cells; data not shown). However, when c-Rel is transiently expressed in NIH3T3 (data not shown) or COS (Fig. 3b) cells, which have a low level of endogenous NF-B, the half-life is reduced. Similarly, it was reported that the inhibitor IB␣ has a short half-life when expressed in its free state but is significantly stabilized when complexed with RelA or c-Rel (40 -42) .
Many substrates of the Ub-Pr pathway contain the acidic PEST sequences, which are defined as the regions enriched in proline, glutamate, serine, and threonine, and are uninterrupted by positively charged residues (43) . The precise mechanism of how a PEST sequence is recognized by the Ub-Pr system is not known. It could be recognized by a component of the proteasome or by kinases that function upstream of the proteolysis. Since PEST sequences are rich in serine/threonine phosphorylation sites, it is also possible that phosphorylation of them may induce conformational changes that unmask regions required for proteolysis. We and others previously demonstrated that the C-terminal PEST sequences of IB␣ are required for its degradation (24, 44, 45) . C-terminally truncated IB␣ is resistant to the Ub-Pr degradation and acts as a dominant mutant. Moreover, the C-terminal PEST sequence of NF-B-1 p105 also plays an important role in its processing; it was shown by MacKichan et al. (46) that phosphorylation of the PEST sequences of p105 up-regulates the proteolytic process- ing of p105 into the active p50. Examination of human c-Rel sequence (47) revealed that the C-terminal region of the molecule is highly enriched in PEST sequences. In the C-terminal 80 amino acids, no arginine or lysine is found, and 30 out of 80 residues are PEST sequences. A similar observation was also made in avian c-Rel protein (35, 48) .
Our in vitro studies showed that C-terminal sequences of c-Rel are important for ubiquitination and degradation (Fig. 7) . All of the C-terminal deletion mutants displayed a certain degree of resistance to in vitro degradation. Interestingly, the region between residues 118 and 171 of c-Rel, i.e. the c-Relspecific sequence immediately following the c-Rel/v-Rel homology domain, appeared to play an important role in mediating ubiquitin conjugation and the subsequent degradation. However, based on the low levels of conjugates detected in ⌬275 and ⌬313, this region is probably not the absolute requirement for conjugation. The biological significance of a C-terminal deletion of c-Rel was first documented by the observation that removal of 55 C-terminal amino acids of c-Rel significantly enhanced its ability to transform splenic cells in vitro (35, 49) . In an attempt to determine the in vivo evolution of c-rel oncogenic potential, we previously inserted c-rel into an REV-T-based retroviral vector and infected 1-day-old chicks (50) . All birds developed tumors, and all cell lines established from the tumors expressed c-Rel proteins that lacked C-terminal sequences. These truncated proteins are probably responsible for both in vivo and in vitro cell proliferation and are selected for their oncogenic potential. Our present finding of an elevated resistance to degradation in C-terminally truncated c-Rel mutants seems to suggest a correlation between oncogenic transformation and a reduced susceptibility to the Ub-Pr-mediated degradation. Our preliminary data showing a much reduced in vitro degradation of v-Rel (data not shown) is consistent with this contention. In agreement with these findings, deletion of the PEST sequences in c-Fos resulted in oncogenic v-Fos, which has a much reduced susceptibility to Ub-Pr-mediated degradation (51) .
Phosphorylation and dephosphorylation have frequently been found coupled with the Ub-Pr pathways. For example, the degradation of cyclin and IB␣ requires an upstream phosphorylation event, and the phosphorylation of c-Jun targets the degradation of c-Fos in AP-1 complexes (51, 52) . On the other hand, phosphorylation of Ser3 of c-Mos prevents its degradation (53) . Presently, we do not know whether phosphorylation of c-Rel is required for the Ub-Pr degradation. It has been reported that c-Rel is highly phosphorylated immediately after NF-B stimulation (32, 54) , and a protein kinase A phosphorylation site toward the C-terminal end of the Rel homology domain is essential for c-Rel activation (55) . It would be interesting to determine whether the phosphorylation-defective cRel mutants are regulated by the Ub-Pr pathway.
